Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.56 |
| ▸ | GP6 | Q9HCN6 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RHEB | Q15382 | 2/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086482 | 1.00 | MRGPRX4 (0.56) | MRGPRX4KDM4CGP6ALDH1A1LMNA | |
| SCHEMBL27764487 | 0.80 | MRGPRX4 (0.54) | MRGPRX4KDM4CGP6 | |
| SCHEMBL400222 | 0.78 | KMT2A (0.67) | GP6ALDH1A1LMNACYP2C9CYP2C19 | |
| SCHEMBL1248713 | 0.77 | SLC22A12 (0.68) | MRGPRX4GP6 | |
| SCHEMBL7793991 | 0.77 | XDH (0.53) | MRGPRX4 | |
| SCHEMBL1055391 | 0.77 | PRMT5 (0.47) | MRGPRX4ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8611753 | 0.76 | XDH (0.49) | MRGPRX4 | |
| SCHEMBL8615451 | 0.76 | MRGPRX4 (0.50) | MRGPRX4 | |
| SCHEMBL7901106 | 0.75 | GRIK1 (0.55) | KDM4CGP6AGTR1AGTR2 | |
| SCHEMBL1060735 | 0.75 | NPC1 (0.54) | MRGPRX4KDM4CALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-102459222-B | L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators | PFIZER | 2014-06-04 | — | — | CN | disclosed |
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103298801-A | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as GPR 119 modulators | PFIZER | 2013-09-11 | — | — | CN | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| CN-102459222-A | L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators | PFIZER | 2012-05-16 | — | — | CN | disclosed |
| EP-2438051-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
| WO-2010140092-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020460-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR88 | MRGPRX4 57/4885KDM4C 4670/4885GP6 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.